Drugs / Aluminum Phosphate
Aluminum Phosphate
also known as
aluminum · ACH · aluminium phosphate · aluminum acetate · Aluminum Adjuvant · Aluminum Chloride · Aluminum Chloride Hexahydrate · Maalox
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | DOMEBORO | — | 1976-04-30 | fda.gov ↗ |
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07401277 | Feb 2026 → Jul 2027 expected | actinic keratosis | West Virginia University | Recruiting | No outcome recorded |
| Phase 1 | NCT02304185 | Dec 2014 → Apr 2016 | — | Crucell Holland BV | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06748404 | Mar 2025 → Dec 2027 expected | — | University of California, San Diego | Recruiting | No outcome recorded |
| Phase 2 | NCT01960686 | Oct 2013 → Apr 2014 | respiratory syncytial virus infectious disease | Novavax | Completed | No outcome recorded |
| Comparator or background therapy4 trials | ||||||
| Phase 1 | NCT03416348 Comparator | May 2018 → Jan 2022 | isolated hyperchlorhidrosis | University of Utah | Completed | No outcome recorded |
| Phase 1 | NCT00347555 Background | May 2006 → Apr 2008 | Plasmodium falciparum malaria | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1/2 | NCT02935686 Background | Mar 2017 → Nov 2023 | — | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
| — | NCT02273570 Background | Mar 2015 → Dec 2016 | secondary hyperparathyroidism of renal origin | Azienda Ospedaliera Sant'Anna | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-01-18 | Janssen Research & Development, LLC | Results Janssen and Global Partners to Discontinue Phase 3 Mosaico HIV Vaccine Clinical Trial jnj.com ↗
The Mosaico DSMB analysis, based on the data available to date, indicated that the regimen does not protect against HIV and the study is not expected to meet its primary endpoint. |
| 2021-08-31 | Janssen Research & Development, LLC | Results Johnson & Johnson and Global Partners Announce Results from Phase 2b Imbokodo HIV Vaccine Clinical Trial in Young Women in Sub-Saharan Africa jnj.com ↗
Data showed the investigational HIV vaccine regimen did not provide sufficient protection against HIV infection in a population of young women in sub-Saharan Africa at high risk of acquiring HIV. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-01-18 | Janssen Research & Development, LLC | Janssen and Global Partners to Discontinue Phase 3 Mosaico HIV Vaccine Clinical Trial jnj.com ↗ |
| 2021-08-31 | Janssen Research & Development, LLC | Johnson & Johnson and Global Partners Announce Results from Phase 2b Imbokodo HIV Vaccine Clinical Trial in Young Women in Sub-Saharan Africa jnj.com ↗ |
| 2011-09-09 | Astellas Pharma Inc | Transfer of Distribution Rights for Targocid® and Maalox® astellas.com ↗ |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | aluminum phosphate | “The gp140 vaccine containing 50 mcg total protein mixed with 0.425 milligram (mg) aluminum phosphate adjuvant will be administered intramuscularly on Day 1 and Day 29.” NCT02304185 ↗2“Clade C gp140 vaccine containing 250 mcg of total protein, mixed with aluminum phosphate adjuvant, per 0.5 milliliter (mL) injection administered intramuscularly.” NCT02935686 ↗ |
| Known as | ACH | “5% 5-fluorouracil (5-FU) powder PLUS 15% Aluminum Chloride Hexahydrate (ACH)” NCT07401277 ↗ |
| Known as | aluminium phosphate | “Ad26.Mos4.HIV vaccine + Clade C glycoprotein 140 vaccine containing 250 microgram (mcg) of total protein mixed with adjuvant (aluminium phosphate) at Week 24 and 48.” NCT02935686 ↗ |
| Known as | aluminum | “A rescue therapy with aluminum("Maalox®") is allowed for no more than 30 days.” NCT02273570 ↗ |
| Known as | aluminum acetate | “TriCalm Hydrogel® is available over-the-counter and contains the active ingredient, aluminum acetate 0.2%, and inactive ingredient, strontium chloride hexahydrate.” NCT06748404 ↗ |
| Known as | Aluminum Adjuvant | “Dose 1 of Aluminum Adjuvant” NCT01960686 ↗ |
| Known as | Aluminum Chloride | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03416348 ↗ |
| Known as | Aluminum Chloride Hexahydrate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07401277 ↗ |
| Known as | Maalox | “A rescue therapy with aluminum("Maalox®") is allowed for no more than 30 days.” NCT02273570 ↗ |
| Modality | Other / unclassified | “aluminum adjuvant” NCT01960686 ↗ |
| Route | Intramuscular | “Clade C gp140 vaccine containing 250 mcg of total protein, mixed with aluminum phosphate adjuvant, per 0.5 milliliter (mL) injection administered intramuscularly.” NCT02935686 ↗ |